Levothyroxine Therapy in Thyrodectomized Patients.

Area of Science:

• Endocrinology
• Pharmacology
• Surgical Oncology

Background:

• Levothyroxine (LT4) replacement is essential post-thyroidectomy to maintain euthyroidism.
• Suboptimal LT4 dosage can lead to hypothyroidism or thyrotoxicosis, impacting patient well-being.
• Limited research focuses on LT4 dosing specifically after thyroidectomy compared to primary hypothyroidism.

Purpose of the Study:

• To review and compare methods for calculating optimal LT4 dosage after total thyroidectomy.
• To explore the limitations and drawbacks of current LT4 replacement therapy in post-thyroidectomy patients.
• To identify factors influencing LT4 dose requirements and absorption.

Main Methods:

• A literature review was conducted, focusing on studies from the last 15 years addressing LT4 therapy post-thyroidectomy.
• Papers detailing schemes for calculating proper LT4 doses were collected and analyzed.
• Existing methods, primarily empirical dosing (1.6 μg/kg), were compared against patient outcomes and influencing factors.

Main Results:

• Empirical LT4 dosing (approx. 1.6 μg/kg) requires adjustment in approximately 75% of patients.
• Factors influencing LT4 dosage include compliance, formulation changes, body mass, diet, and drug interactions.
• Gastrointestinal conditions and certain medications (e.g., calcium, iron) can impair LT4 absorption, especially for solid formulations.

Conclusions:

• Standard empirical LT4 dosing post-thyroidectomy is often insufficient, necessitating individualized adjustments.
• Multiple patient-specific factors and drug interactions complicate LT4 therapy, highlighting the need for tailored approaches.
• Newer LT4 formulations, like oral solutions, may improve absorption and overcome food-related interferences.